

DTC FILE COPY

AD____

STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS

Annual Report

B. R. DasGupta

March 20, 1987

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD17-84-C-4245

University of Wisconsin Madison, Wisconsin 53706

Approved for public release; distribution unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.



13. REPORT SECURITY CLASSIFICATION 14. REPORT SECURITY CLASSIFICATION 25. SECURITY CLASSIFICATION AUTHORITY 26. DECLASSIFICATION/DOWNGRADING SCHEDULE 27. PERFORMING ORGANIZATION REPORT NUMBER(S) 28. NAME OF PERFORMING ORGANIZATION REPORT NUMBER(S) 29. NAME OF PERFORMING ORGANIZATION REPORT NUMBER(S) 29. NAME OF PERFORMING ORGANIZATION FOOD Research Institute 20. OFFICE SYMBOL (If applicable) 20. ADDRESS (City, State, and ZIP Code) 21. University of Wisconsin-Madison Madison, Wisconsin 53706 29. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER ORGANIZATION (If applicable) 29. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-84-C-4245 29. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-84-C-4245 20. SOURCE OF FUNDING INDUSTRY 20. SOURCE OF FUNDING NUMBERS 21. SOURCE OF FUNDING NUMBERS 21. TITLE (Include Security Classification) 21. TITLE (Include Security Classification) 21. PERSONAL AUTHOR(S) 21. DESTRIBUTION / AVAILABILITY OF REPORT (Year, Month, Day) (15. PAGE COUNT 1987, March, 20 8) 21. SUPPLEMENTARY NOTATION 21. SUPPLEMENTARY NOTATION 22. SECURITY CLASSIFICATION AUTHORY 23. DISTRIBUTION / AVAILABILITY OF REPORT (Year, Month, Day) (15. PAGE COUNT 1987, March, 20 8)	1a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED 1b. RESTRICTIVE MARKINGS 1c. SECURITY CLASSIFICATION AUTHORITY 2b. DECLASSIFICATION AUTHORITY 2c. DECLASS	SECURITY CLASSIFICATION OF THIS PAGE		4D-A		
28. SECURITY CLASSIFICATION AUTHORITY 29. DECLASSIFICATION AUTHORITY 29. DECLASSIFICATION AUTHORITY 20. DECLASSIFICATION AUTHORITY 20. DECLASSIFICATION AUTHORITY 21. DECLASSIFICATION PROPERT NUMBER(S) 22. SECURITY CLASSIFICATION AUTHORITY 23. DISTRIBUTION /AVAILABILITY OF REPORT Approved for public release; distribution unlimited 3. DISTRIBUTION /AVAILABILITY OF REPORT Approved for public release; distribution unlimited 3. DISTRIBUTION /AVAILABILITY OF REPORT Approved for public release; distribution unlimited 3. DISTRIBUTION /AVAILABILITY OF REPORT Approved for public release; distribution unlimited 3. DISTRIBUTION /AVAILABILITY OF REPORT Approved for public release; distribution unlimited 3. DISTRIBUTION /AVAILABILITY OF REPORT Approved for public release; distribution unlimited 3. DISTRIBUTION /AVAILABILITY OF REPORT Approved for public release; distribution unlimited 3. DISTRIBUTION /AVAILABILITY OF REPORT Approved for public release; distribution unlimited 5. MONITORING ORGANIZATION REPORT NUMBER(S) 7a. NAME OF MONITORING ORGANIZATION 7b. ADDRESS (City, State, and ZIP Code) 7c. ADDRESS (City, State, and ZIP Code) 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT ELEMENT NO. NO. 3M1-NO. ACCESSION 62770AB 71 AB 362 11. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 12. PERSONAL AUTHOR(S) DASGUPTA, B. R. 13b. TIME COVERED FROM 9/15/85 TO 9/14/86 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT Annual 16. SUPPLEMENTARY NOTATION	UNICLASSIFIED 2a. SECURITY CLASSIFICATION AUTHORITY 2b. DECLASSIFICATION / DOWINGRADING SCHEDULE Approved for public release; distribution unlimited 5. MONITORING ORGANIZATION REPORT NUMBER(S) 5. MONITORING ORGANIZATION REPORT NUMBER(S) 6b. OFFICE SYMBOL (If applicable) 6c. ADDRESS (City, State, and ziP code) University of Wisconsin-Madison Madison, Wisconsin 53706 6a. NAME OF FUNDING/SPONSORING ORGANIZATION Madison, Wisconsin 53706 6b. OFFICE SYMBOL (If applicable) 7c. ADDRESS (City, State, and ziP code) University of Wisconsin 53706 6c. ADDRESS (City, State, and ziP code) University of Wisconsin 53706 6d. ADDRESS (City, State, and ziP code) 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT ELEMENT NO. SMI PROJECT ELEMENT NO. SMI NO. SMI NO. ACCESSION NO. SMI NO. ACCESSION NO. 6277CA 62770A871 AB 362 11. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 13b. TIME COVERED FROM 13b. TIME COVERED FROM 9/15/85 to 9/14/86 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT 1987, March, 20 18. SUPPLEMENTARY NOTATION 18. SUPPLEMENTARY NOTATION 18. SUBJECT TERMS (Continue on reverse if necessary and Identify by block number) Neurotoxin of type B strain 657, amino acid sequence, RA 1 fragments of type A, B, E neurotoxin, role of Lys and Tyr residues, second generatior toxoid, tertiary structure of	REPORT DOCUMENTATION	ON PAGE			
Approved for public release; distribution unlimited 4. PERFORMING ORGANIZATION REPORT NUMBER(S) 5. MONITORING ORGANIZATION REPORT NUMBER(S) 7. NAME OF MONITORING ORGANIZATION FOOD Research Institute 6. ADDRESS (City, State, and ZiP Code) University of Wisconsin-Madison Madison, Wisconsin 53706 8. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Commend 8. ADDRESS (City, State, and ZiP Code) Fort Detrick Fort Detrick Fort Detrick Frederick, Maryland 21701-5012 TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 12. PERSONAL AUTHOR(S) DAMD17-84-C-4245 13. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT ELEMENT NO. 3M1- NO. 3	Approved for public release; distribution unlimited 1. PERFORMING ORGANIZATION REPORT NUMBER(S) 1. NAME OF PERFORMING ORGANIZATION FOOD Research Institute 1. ADDRESS (City, State, and ZiP Code) 1. University of Wisconsin-Madison Madison Wisconsin 53706 1. NAME OF PUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command 1. ADDRESS (City, State, and ZiP Code) 1. TITLE (Include Security Classification) 1. TITLE (Include Security Classification) 1. TITLE (Include Security Classification) 1. STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHORIS) 2. SUPPLEMENTARY NOTATION 1. SUPPLEMENTARY NOTATION 1. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) 1. Received of type A B E reurotoxin, role of Lys and Type of Lype A, B in evertee of type	1a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED	16. RESTRICTIVE	MARKINGS		
distribution unlimited 4. PERFORMING ORGANIZATION REPORT NUMBER(S) 5. MONITORING ORGANIZATION REPORT NUMBER(S) 7. NAME OF MONITORING ORGANIZATION 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-84-C-4245 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT NO. 3M1- NO. MONITORING ORGANIZATION 11. TITLE (Include Security Classification) 11. TITLE (Include Security Classification) 12. PERSONAL AUTHOR(S) 13. TYPE OF REPORT ANNUAL 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT ROUSE 16. SUPPLEMENTARY NOTATION	distribution unlimited 1. PERFORMING ORGANIZATION REPORT NUMBER(S) 5. MONITORING ORGANIZATION REPORT NUMBER(S) 7. NAME OF PERFORMING ORGANIZATION FOOD Research Institute 6. OFFICE SYMBOL (If applicable) 7. NAME OF MONITORING ORGANIZATION 7. ADDRESS (City, State, and ZiP Code) 8. OFFICE SYMBOL (If applicable) 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-84-C-4245 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT TASK NO. 3M1 NO. 3M1 NO. 3M1 NO. 3M1 NO. ACCESSION NO. 3M1 NO. 3M1 NO. ACCESSION NO. ACCESSION NO. ACCESSION NO		3. DISTRIBUTION	/AVAILABILITY O	F REPORT	
5. MONITORING ORGANIZATION REPORT NUMBER(S) 75. NAME OF MONITORING ORGANIZATION 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-84-C-4245 10. SOURCE OF FUNDING NUMBERS PROJECT 10. SOURCE OF FUNDING NUMBERS PRO	S. MONITORING ORGANIZATION REPORT NUMBER(S) 7a. NAME OF MONITORING ORGANIZATION FOR Research Institute C. ADDRESS (City, State, and ZiP Code) University of Wisconsin-Madison Madison, Wisconsin 53706 4. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command C. ADDRESS (City, State, and ZiP Code) DAMD17-84-C-4245 C. ADDRESS (City, State, and ZiP Code) DAMD17-84-C-4245 DAMD17-84-C-4245 TO SOURCE OF FUNDING NUMBERS PROGRAM FOR TO NO. 3M1. ELEMENT NO. 3M1. 62770A 62770A871 AB 362 TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTUL INUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DASGUPTA, B. R. 33. TYPE OF REPORT FROM 9/15/85 TO 9/14/86 FROM 9/15/85 TO 9/14/86 FIELD GROUP SUB-GROUP FIELD GROUP	2b. DECLASSIFICATION / DOWNGRADING SCHEDULE				
For Detrick Ford Detrick, Maryland 21701–5012 1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTUL INUM NEUROTOXINS (U) 5. ADDRESS (City, State, and ZIP Code) (If applicable) 7. NAME OF MONITORING ORGANIZATION 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-84-C-4245 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT TASK WORK UN ELEMENT NO. 3M1 ACCESSION NO. 3M1 AB 362 1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DASGUPTA B. R. 3. TYPE OF REPORT 13b. TIME COVERED FROM 9/15/85 TO 9/14/86 6. SUPPLEMENTARY NOTATION	Food Research Institute C. ADDRESS (City, State, and ZiP Code) University of Wisconsin-Madison Madison, Wisconsin 53706 a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command C. ADDRESS (City, State, and ZiP Code) DAMD17-84-C-4245 C. ADDRESS (City, State, and ZiP Code) DAMD17-84-C-4245 C. ADDRESS (City, State, and ZiP Code) DAMD17-84-C-4245 Fort Detrick Frederick, Maryland 21701-5012 1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 3a. Type of REPORT Annual FROM 9/15/85 TO 9/14/86 14. Date Of REPORT (Year, Month, Day) T. COSATI CODES FIELD GROUP SUB-GROUP FIELD GROUP SUB-GROUP Tragments of type A, B, E neurotoxin, role of Lys and Tyr residues, second generatior toxoid, tertiary structure of	4. PERFORMING ORGANIZATION REPORT NUMBER(S)				/S\
Food Research Institute Sc. ADDRESS (City, State, and ZIP Code) University of Wisconsin-Madison Madison, Wisconsin 53706 A. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command C. ADDRESS (City, State, and ZIP Code) Fort Detrick Fort Detrick Frederick, Maryland 21701-5012 1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 3a. TYPE OF REPORT Annual 13b. TIME COVERED FROM 9/15/85 TO 9/14/86 14. DATE OF REPORT (Year, Month, Day) 19. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-84-C-4245 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT NO. 3M1 6277CA 6277CA871 AB 362 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT 1987, March, 20 8	Food Research Institute C. ADDRESS (City, State, and ZiP Code) University of Wisconsin-Madison Madison, Wisconsin 53706 a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command C. ADDRESS (City, State, and ZiP Code) Fort Detrick Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 3M1	THE STANDARD OF THE PROPERTY O	3. MONTOKING	ORGANIZATION R	EPORT NOWIBER	(3)
University of Wisconsin-Madison Madison, Wisconsin 53706 A. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command Bb. Office Symbol ORGANIZATION U.S. Army Medical Research & Development Command DAMD17-84-C-4245	University of Wisconsin-Madison Madison, Wisconsin 53706 a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command c. ADDRESS (City, State, and ZiP Code) Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT NO. 3M1 NO. 3	(If poplicable)	7a. NAME OF MO	ONITORING ORGA	NIZATION	
Madison, Wisconsin 53706 a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command Research & Development Command c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012 1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DAMD17-84-C-4245 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT ELEMENT NO. 3M1 NO. 3M1 NO. ACCESSION 6277CA 6277CA 6277CA871 AB 362 1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DASGUPTA, B. R. 33. TYPE OF REPORT FROM 9/15/85 TO 9/14/86 1987, March, 20 8 15. PAGE COUNT ROOM 9/15/85 TO 9/14/86 1987, March, 20 8	Madison, Wisconsin 53706 a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command C. ADDRESS (City, State, and ZiP Code) Fort Detrick Frederick, Maryland 21701-5012 1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 3a. TYPE OF REPORT Annual 13b. TIME COVERED FROM 9/15/85 to 9/14/86 14. Date Of Report (Year, Month, Day) 15. PAGE COUNT 1987, March, 20 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Neurotoxin of type B strain 657, amino acid sequence, RA 1 fragments of type A, B, E neurotoxin, role of Lys and Tyr residues, second generatior toxoid, tertiary structure of	c. ADDRESS (City, State, and 2iP Code)	7b. ADDRESS (Cit	y, State, and ZIP	Code)	
ORGANIZATION U.S. Army Medical Research & Development Command Research & Development Command C. ADDRESS (City, State, and ZiP Code) Fort Detrick Frederick, Maryland 21701–5012 10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 3M1 NO.	ORGANIZATION U.S. Army Medical Research & Development Command DAMD17-84-C-4245 C. ADDRESS (City, State, and ZiP Code) Fort Detrick Frederick, Maryland 21701-5012 10. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT NO. 3M1 NO. 3M1 NO. 3M1 NO. 3M1 NO. 3M2 NO. 3M2 NO. 3M3 NO. ACCESSION NO. 3M4 NO. 3M4 NO. 3M4 NO. 3M4 NO. 3M4 NO. 3M5 NO. ACCESSION NO. 3M6 NO.					
Research & Development Command DAMD17-84-C-4245 ID. SOURCE OF FUNDING NUMBERS PROGRAM PROJECT TASK NO. 3M1 NO. 3M1 NO. 3M1 NO. MACCESSION Fort Detrick Frederick, Maryland 21701-5012 1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 3a. TYPE OF REPORT Annual FROM 9/15/85 TO 9/14/86 6. SUPPLEMENTARY NOTATION	Research & Development Command C. ADDRESS (City, State, and ZiP Code) Fort Detrick Frederick, Maryland 21701-5012 TASK NO. 3M1 NO.	Bb. OFFICE SYMBOL	9. PROCUREMENT	T INSTRUMENT ID	ENTIFICATION N	UMBER
Fort Detrick Frederick, Maryland 21701-5012 1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 33. TYPE OF REPORT Annual 13b. TIME COVERED FROM 9/15/85 to 9/14/86 14. Date Of Report (Year, Month, Day) FROM 9/15/85 to 9/14/86 1987, March, 20 15. PAGE COUNT 1987, March, 20 16. SUPPLEMENTARY NOTATION	Fort Detrick Frederick, Maryland 21701–5012 57 TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) TOXIC ANTIGENIC ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) TOXIC ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) TOXIC ANTIGENIC ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) TOXIC ANTIGENIC ANTIGENI		DAMD17-84	-C-4245		
Fort Detrick Frederick, Maryland 21701-5012 1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 33. TYPE OF REPORT Annual 13b. TIME COVERED FROM 9/15/85 to 9/14/86 14. Date Of Report (Year, Month, Day) 15. PAGE COUNT 1987, March, 20 8	Fort Detrick Frederick, Maryland 21701-5012 1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 33. TYPE OF REPORT Annual FROM 9/15/85 to 9/14/86 34. DATE OF REPORT (Year, Month, Day) FROM 9/15/85 to 9/14/86 35. SUPPLEMENTARY NOTATION 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Neurotoxin of type B strain 657, amino acid sequence, RA 1 fragments of type A, B, E neurotoxin, role of Lys and Tyr residues, second generatior toxoid, tertiary structure of	c. ADDRESS (City, State, and ZIP Code)				IWORK HOUT
1. TITLE (Include Security Classification) STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 3a. TYPE OF REPORT Annual 13b. TIME COVERED FROM 9/15/85 to 9/14/86 14. Date Of Report (Year, Month, Day) FROM 9/15/85 to 9/14/86 1987, March, 20 8	STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 3a. TYPE OF REPORT Annual FROM 9/15/85 TO 9/14/86 7. COSATI CODES FIELD GROUP SUB-GROUP O6 01 Fragments of type A, B, E neurotoxin, role of Lys and Tyr residues, second generatior toxoid, tertiary structure of					ACCESSION NO
STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 3a. TYPE OF REPORT Annual 13b. TIME COVERED FROM 9/15/85 TO 9/14/86 14. DATE OF REPORT (Year, Month, Day) FROM 9/15/85 TO 9/14/86 1987, March, 20 8	STUDY OF TOXIC AND ANTIGENIC STRUCTURES OF BOTULINUM NEUROTOXINS (U) 2. PERSONAL AUTHOR(S) DasGupta, B. R. 3a. TYPE OF REPORT Annual FROM 9/15/85 to 9/14/86 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT 1987, March, 20 8 6. SUPPLEMENTARY NOTATION 7. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Neurotoxin of type B strain 657, amino acid sequence, RA 1 fragments of type A, B, E neurotoxin, role of Lys and Tyr 196 20 residues, second generation toxoid, tertiary structure of		6277CA	62770A871	AB	362
2. PERSONAL AUTHOR(S) DasGupta, B. R. 3a. TYPE OF REPORT Annual 13b. TIME COVERED FROM 9/15/85 to 9/14/86 14. Date Of Report (Year, Month, Day) FROM 9/15/85 to 9/14/86 1987, March, 20 8 6. SUPPLEMENTARY NOTATION	2. PERSONAL AUTHOR(S) DasGupta, B. R. 3a. TYPE OF REPORT Annual FROM 9/15/85 to 9/14/86 14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT 1987, March, 20 8 6. SUPPLEMENTARY NOTATION 7. COSATI CODES FIELD GROUP SUB-GROUP 06 01 Fragments of type B strain 657, amino acid sequence, RA 1 fragments of type A, B, E neurotoxin, role of Lys and Tyr residues, second generatior toxoid, tertiary structure of					
DasGupta, B. R. 3a. Type of report 13b. Time covered 14. Date of report (Year, Month, Day) 15. Page count from 9/15/85 to 9/14/86 1987, March, 20 8 6. Supplementary notation	DasGupta, B. R. 3a. TYPE OF REPORT Annual FROM 9/15/85 TO 9/14/86 14. Date Of REPORT (Year, Month, Day) FROM 9/15/85 TO 9/14/86 1987, March, 20 8 6. SUPPLEMENTARY NOTATION TO COSATI CODES FIELD GROUP SUB-GROUP Neurotoxin of type B strain 657, amino acid sequence, RA 1 fragments of type A, B, E neurotoxin, role of Lys and Tyr O6 20 Fresidues, second generatior toxoid, tertiary structure of		TULINUM NEURO	TOXINS (U)		
Annual FROM <u>9/15/85</u> to <u>9/14/86</u> 1987, March, 20 8 6. SUPPLEMENTARY NOTATION	Annual FROM 9/15/85 to 9/14/86 1987, March, 20 8 6. SUPPLEMENTARY NOTATION TO COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Neurotoxin of type B strain 657, amino acid sequence, RA 1 O6 01 fragments of type A, B, E neurotoxin, role of Lys and Tyr O6 20 residues, second generatior toxoid, tertiary structure of	2. PERSONAL AUTHOR(S) DasGupta, B. R.				
6. SUPPLEMENTARY NOTATION	6. SUPPLEMENTARY NOTATION 7. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Neurotoxin of type B strain 657, amino acid sequence, RA 1 06 01 fragments of type A, B, E neurotoxin, role of Lys and Tyr 06 20 residues, second generatior toxoid, tertiary structure of				Day) 15. PAGE	
	Neurotoxin of type B strain 657, amino acid sequence, RA 1 06 01 fragments of type A, B, E neurotoxin, role of Lys and Tyr 06 20 residues, second generation toxoid, tertiary structure of		1907, Mai	rcii, zu		
	Neurotoxin of type B strain 657, amino acid sequence, RA 1 06 01 fragments of type A, B, E neurotoxin, role of Lys and Tyr 06 20 residues, second generation toxoid, tertiary structure of					
7. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	Neurotoxin of type B strain 657, amino acid sequence, RA 1 06 01 fragments of type A, B, E neurotoxin, role of Lys and Tyr 06 20 residues, second generation toxoid, tertiary structure of	7. COSATI CODES 18. SUBJECT TERMS	(Continue on reverse	e if necessary and	identify by blo	ck number)
	06 20 residues, second generation toxoid, tertiary structure of					
The neurotoxin (NT) from type B (strain 657) was partially sequenced (44 residues from 1		chain and 26 residues from heavy chain). Sign	nificant sequ	ence homolo	gy between	this type !
The neurotoxin (NT) from type B (strain 657) was partially sequenced (44 residues from 1 chain and 26 residues from heavy chain). Significant sequence homology between this type	chain and 26 residues from heavy chain). Significant sequence homology between this type	Jotulinum and tetanus NIS are now evident. A	second proced	dure was der	veloped to	enzymatica
The neurotoxin (NT) from type B (strain 657) was partially sequenced (44 residues from 1 chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymatic	chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymatica	sequenced. Secondary structures of types A a	nd F NT in te	rms of the	gments was liv and R\s	partially
The neurotoxin (NT) from type B (strain 657) was partially sequenced (44 residues from 1 chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymaticleave the heavy chain of type A NT into two halves; one of these fragments was partially	chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymatica cleave the heavy chain of type A NT into two halves; one of these fragments was partially	were determined. Changes in conformation (hyd	drophobicity)	were detect	ted when si	ingle chain
The neurotoxin (NT) from type B (strain 657) was partially sequenced (44 residues from 1 chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymaticleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of a helix and beside conversed. Changes in conformation (hydrophobicity) were detected when single cha	chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymatica cleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of helix and scheet contewere determined. Changes in conformation (hydrophobicity) were detected when single chain	type E NT was nicked to the dichain form. Ro	les of i) Lys	residues i	n types A a	ind B NT, ar
The neurotoxin (NT) from type B (strain 657) was partially sequenced (44 residues from 1 chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymaticleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of a helix and become sheet converse determined. Changes in conformation (hydrophobicity) were detected when single chatype E NT was nicked to the dichain form. Roles of i) Lys residues in types A and B NT,	chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymatica cleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of the lix and sheet contewere determined. Changes in conformation (hydrophobicity) were detected when single chain type E NT was nicked to the dichain form. Roles of i) Lys residues in types A and B NT, a	ιιι ίνη γρεταμός τη τυπός Δ. Κ. Άνη Ε. Νί Μόγο (studied based toxicity an	on cnemica d chance in	MOGITICAT	cion and
The neurotoxin (NT) from type B (strain 657) was partially sequenced (44 residues from 1 chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymaticleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of a helix and be sheet convere determined. Changes in conformation (hydrophobicity) were detected when single chatype E NT was nicked to the dichain form. Roles of i) Lys residues in types A and B NT, ii) Tyr residues in types A, B and E NT were studied based on chemical modification and	chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymatica cleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of helix and sheet conte were determined. Changes in conformation (hydrophobicity) were detected when single chain type E NT was nicked to the dichain form. Roles of i) Lys residues in types A and B NT, a li) Tyr residues in types A, B and E NT were studied based on chemical modification and	Quantitative assay of amino acid modification		u change III	3610104100	ιι αυυινίζε
The neurotoxin (NT) from type B (strain 657) was partially sequenced (44 residues from 1 chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymaticleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of helix and sheet convere determined. Changes in conformation (hydrophobicity) were detected when single chatype E NT was nicked to the dichain form. Roles of i) Lys residues in types A and B NT, ii) Tyr residues in types A, B and E NT were studied based on chemical modification and quantitative assay of amino acid modification, toxicity and change in serological activity	chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymatica cleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of helix and sheet contewere determined. Changes in conformation (hydrophobicity) were detected when single chain type E NT was nicked to the dichain form. Roles of i) Lys residues in types A and B NT, a ii) Tyr residues in types A, B and E NT were studied based on chemical modification and quantitative assay of amino acid modification, toxicity and change in serological activity	quantitative assay of amino acid modification	ification of	Tyr residues	s was a goo	d immunogen
The neurotoxin (NT) from type B (strain 657) was partially sequenced (44 residues from 1 chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymaticleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of a helix and sheet con were determined. Changes in conformation (hydrophobicity) were detected when single chatype E NT was nicked to the dichain form. Roles of i) Lys residues in types A and B NT, ii) Tyr residues in types A, B and E NT were studied based on chemical modification and quantitative assay of amino acid modification, toxicity and change in serological activity and completely detoxified following modification of Tyr residues was a good immunor	chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymatica cleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of helix and sheet contewere determined. Changes in conformation (hydrophobicity) were detected when single chain type E NT was nicked to the dichain form. Roles of i) Lys residues in types A and B NT, a ii) Tyr residues in types A, B and E NT were studied based on chemical modification and quantitative assay of amino acid modification, toxicity and change in serological activity Type B NT completely detoxified following modification of Tyr residues was a good immunoge	quantitative assay of amino acid modification Type B NT completely detoxified following mod	ification of	Tyr residues	s was a goo	od immunoger
The neurotoxin (NT) from type B (strain 657) was partially sequenced (44 residues from 1 chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymaticleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of the heavy chain sheet conwere determined. Changes in conformation (hydrophobicity) were detected when single chatype E NT was nicked to the dichain form. Roles of i) Lys residues in types A and B NT, ii) Tyr residues in types A, B and E NT were studied based on chemical modification and quantitative assay of amino acid modification, toxicity and change in serological activity.	chain and 26 residues from heavy chain). Significant sequence homology between this type botulinum and tetanus NTs are now evident. A second procedure was developed to enzymatica cleave the heavy chain of type A NT into two halves; one of these fragments was partially sequenced. Secondary structures of types A and E NT in terms of helix and sheet contewere determined. Changes in conformation (hydrophobicity) were detected when single chain type E NT was nicked to the dichain form. Roles of i) Lys residues in types A and B NT, a ii) Tyr residues in types A, B and E NT were studied based on chemical modification and quantitative assay of amino acid modification, toxicity and change in serological activity Type B NT completely detoxified following modification of Tyr residues was a good immunoge	quantitative assay of amino acid modification. Type B NT completely detoxified following mod	ification of	Tyr residues	s was a goo	od immunogen

UNCLASSIFIED/UNLIMITED 🔟 SAME AS RPT.	☐ DTIC USERS	UNCLASSIFIED	
22a. NAME OF RESPONSIBLE INDIVIDUAL Mary F. Bostian		22b. TELEPHONE (Include Area Code) 301/663~7325	22c. OFFICE SYMBOL SGRD-RMI-S
DD Form 1473 IIIN 86	Previous aditions are o	chsolete SECURITY C	ASSIGNATION OF THIS PAGE

SUMMARY

The type B neurotoxin (NT) isolated from Clostridium botulinum (strain 657) behaved as a mixture of single (unnicked) and dichain (nicked) protein both of $M_r \sim 150K$. When reduced with mercaptoethanol the two chains from the dichain NT were separated and migrated in SDS-PAGE as polypeptides of M_r 100 and 50K similar to the H and L chains of other serotypes of botulinum NT. The N-terminal sequences of the two chains were determined. A procedure, different from that reported earlier, was developed to produce and purify the two halves of the H chain of type A NT. Amino acid composition and partial amino acid sequence of the C-terminal half was determined. Conformations of dichain type A (nicked by endogenous protease), single chain type E and dichain type E (nicked by trypsin) were compared at different pHs using circular dichroism and fluorescence spectroscopy. Roles of Lys residues in types A and B NTs and Tyr residues in types A, B and E NTs (with respect to their structure-function relationship) were studied based on chemical modification and quantitative assay of amino acid modification, toxicity and change in serological activity. Type B NT completely detoxified following modification of Tyr residues proved to be a good immunogen (second generation toxoid) in rabbits. The antiserum had good NT neutralizing titer.

Accession For	
NTIS GRA&I DTIC TAB Unannounced Justification	BTIC
By	INSPECTE
Availability Codes	_
Avail and/or Dist Special	

FOREWORD

In conducting the research described in this report, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHHS Publication No. (NIK) 86-23, Revised 1985).

BODY OF REPORT

Clostridium botulinum has been a subject of awe and alarm because the ubiquitous spore forming bacteria produce the protein, botulinum neurotoxin, generally regarded as the most poisonous poison $(2x10^{-8} \text{ mg})$ is lethal for a mouse) made by nature, in antigenically distinguishable forms (types A, B, C, D, E, F, and G). The neurotoxin (NT) causes the dreaded neuroparalytic disease botulism (1).

Definitive diagnosis and the only effective therapy for botulism depends, at present, on a chemically modified form(s) of the neurotoxin i.e. toxoid (immunogen) and the antiserum raised against the immunogen. Therapy for botulism is supportive care following neutralization of the circulating NT with type specific antiserum. Protection against botulism through prophylactic immunization is confined only to the laboratory personnel who work with C. botulinum or the NT. A better immunogen, free of side effects, would provide effective prophylactic protection for a population mass (civilians and military) facing potential exposure to the deadly NT (1,2). Mass immunization with tetanus toxoid has essentially wiped out tetanus as a public health problem. The structures of tetanus and botulinum neurotoxins are very similar yet active immunity against tetanus lasts up to about 10 years while booster shots of botulinum toxoid are administered every 2-3 years to maintain good immunity. Crucial for diagnosis and therapy are the type specific antisera and therefore the type specific immunogens. Until about 1960 only types A-E were known. Gradual recognition of types F and G indicates that other unrecognized types are probably present in nature to which we are vulnerable. An unusual type B NT (from strain 657, isolated from human infant botulism) was identified; it is ~5000 x more toxic to infant than adult mice, and it requires ~1000 fold more standard type B antiserum for neutralization than the well known type B NT (3). These facts show our poor understanding of the immunogenic nature of the botulinum NT.

This research activity, part of a long term, ongoing project, was on the i) elucidation of the structure of botulinum NTs, ii) determination of structure-antigenicity relationships, iii) preparation of immunogens (second generation immunogens, see p. 6 for explanation) better than the traditional toxoids.

During this contract period our work covered, i) purification and characterization of the unusual type B NT from strain 657, ii) preparation of second generation toxoids, iii) fragmentation of NT, isolation and characterization of the fragments, iv) determination of amino acid sequence and v) determination of antigenic structures (selective modification of amino acid residues. We initiated examination of conformation based on spectrophotometric and fluorometric methods.

These separate and independent studies are presented in five separate sections each with its experimental method, results, discussions and conclusions.

1. CHARACTERIZATION OF THE NEUROTOXIN FROM TYPE B STRAIN 657:

The strain 657, isolated from a case of human infant botulinum, produced type B toxin that appeared unusual in its serological properties; at least two species of toxic proteins were thought to be involved of which only one corresponds to the type B specificity (Hatheway et al. J. Clin. Microbiol. 14, 607 [1981]). It was also reported that the 657 toxin is a mixture of type B (-95%) and type A toxins and the type B toxin from strain 657 represents the prototype of a new serotype named subtype Ba (Gimenez Zbl. Bakt. Hyg. A. 257, 68 [1984]). This conclusion was based on cross-neutralization tests done with anti-serum prepared against neurotoxin serotypes A, B and B-657.

We purified the 657 toxin following a method of purification of type A rather that that of type B (strain Okra) neurotoxin (NT). Following its purification, the 657 toxin was identified serologically by testing against antitype A and antitype B (strain Okra) NT sera. Also the two chains of the 657 toxin were separated and analyzed for amino acid sequence.

The toxin behaved as a mixture of single (unnicked) and dichain (nicked) protein, both of ~150Ka. When the protein was reduced with mercaptoethanol the two chains migrated in SDS-PAGE as separate polypeptides of $M_{
m r}$ -100K and 50K that appeared similar to the heavy and light chains of other serotypes of botulinum NT. The N-terminal amino acid sequences of the two chains were determined. They were as follows; light chain: Pro.Val.Thr.Ile.Asn.Asn.Phe.Asn.Tyr.Asn.Asp.Pro.Ile.Asp.Asn.Asn.Asn.Ile.Ile. Met.Met.Glu.Pro.Pro.Phe.Ala.Arg.Gly.Met.Gly.Arg.Tyr.Tyr.Lys.Ala.Phe.Lys.Ile. Thr.Asp.Arg.Ile.Trp.Ile.-; and heavy chain: Ala.Pro.Gly.Ile.X.Ile.Asp.Val. Asp.Asn.Glu.Asp.Leu.Phe.Phe.Ile.Ala.Asp.Lys.Asn.Ser.Phe.Arg.Asp.Asp.Leu.-These two sequences matched exactly with those of the light and heavy chains of type B NT (strain Okra) of which only 16 and 18 residues were known (Sathyamoorthy and DasGupta J. Biol. Chem. 260, 10461, 1985). The above sequences were different from those of type A NT. Immunoprecipitation reactions of type B NT isolated from strains 657 and Okra were indistinguishable against polyclonal antitype B NT serum. These two preparations did not produce precipitin reactions with polyclonal antitype A NT serum. The tetanus NT (from <u>Clostridium tetani</u>) resembles botulinum NT in relative molecular mass, dichain structure and probably in the mode of action; but the two NTs differ in their sites of action and their serologic specificity. Comparison of amino acid sequences of type B botulinum NT, reported here, and tetanus NT (Eisel et al. EMBO J. 5, 2495, 1986) shows that their two heavy chains are less homologous (13 out of 26 residues matched in position) than the two light chains (31 out of 44 residues matched). Three stretches residues #3-7, 18-24 and 32-44 on the light chains of the two NTs are identical.

2. ENZYMATIC CLEAVAGE OF THE HEAVY CHAIN AND PARTIAL CHARACTERIZATION OF THE TWO FRAGMENTS:

The two halves, i.e. the N- and C-terminal halves, of the heavy chain of the NT is thought to have different functions in the mechanism of action of the NT (by analogy with diphtheria and tetanus toxin). Well characterized and highly purified preparations of the two halves of the heavy chain are needed for such studies. Two different approaches were taken to cut the heavy chain with trypsin and isolate the fragments. In one method, developed earlier, the intact type A NT (150 KDa) was digested with trypsin to cut the heavy chain. The cleavage products were: i) 94 KDa fragment made of the L chain linked to the N-terminal half of the heavy chain (49 KDa) by a disulfide bond(s), and ii) the C-terminal 44 KDa fragment. The second method developed was as follows: The heavy chain of type A NT was first separated from the light chain, purified and then digested with trypsin. One product of cleavage, the 44 KDa fragment (C-fragment) was chromatographically purified and then analyzed for amino acid composition and sequence. The sequence, given below, matches with the sequence of the C-fragment (only 12 residues were sequenced) obtained by method one (i.e. digestion of intact NT) except at positions 1 and 3.

This work also demonstrated that in type A i) the cysteine residues located on the N-terminal half of the heavy chain forms the HS-S-I link(s) with the light chain. ii) The C-terminal half (44 KDa fragment) is not linked via -S-S- to the L-chain or to the N-terminal half (49 KDa fragment) of the heavy chain.

Digestion of intact type E NT with trypsin also cleaved the heavy chain at about the mid-point. One cleavage product was the light chain linked to the N-terminal half of the heavy chain via disulfide bond(s), hence its total size ~100 KDa. This fragment of the heavy chain was separated from the light chain, chromatographically purified and partially sequenced. Two independent sequence runs gave a sequence (see below) which is identical to the known N-terminal sequence of the intact heavy chain. This confirms that the isolated and purified fragment is the N-terminal half of the heavy chain.

Tryptic fragmentation at about the mid-point of the heavy chain of type B NT has been accomplished at the analytical level.

3. STRUCTURE-FUNCTION RELATIONSHIP:

The role of amino acid residues as structural components of biologically active sites of the NT were examined by specific chemical modification of lysine and tyrosine residues.

Lysine: Type A and B Nis were modified by reductive methylation using NaBH4 and formaldehyde at different molar ratios of the protein and the reagent and then they were analyzed for change in toxicity, serological reactivity and the number of lysine residues modified. Amino acid analysis of the modified proteins (HCl hydrolysed) confirmed selective modification of lysine. The derivative N,N-dimethyl lysine was more abundant than monomethyl lysine; trimethyl lysine was not detected. Distribution of modified lysine residues among the heavy and light chains of the dichain type A NI was approximately proportional to the lysine contents of the two subunits of the NI. Toxicity (mouse lethality) and serological reactivity (polyclonal

antibody) of type A NT were not (or insignificantly) damaged following methylation of up to 72 lysine residues. Modification of 3 additional residues caused precipitious loss in toxicity. The type B NT appeared more susceptible to the effect of lysine modification than type A NT. When 31, 55, 77 or 88 lysine residues of type B NT (out of a total of 118 residues) were modified, mouse death time (31 min for control) was found to be 47, 79, 143 or 186 min, respectively. Difference between type A and B NTs with respect to the effect of modification on toxicity suggests that role of lysine residues in structure-function relationship in these two antigenically distinct proteins may not be identical.

Tyrosine. Type A, B and E NTs were modified at pH 7.9 with tetranitromethane, a reagent highly specific for tyrosine residues. Modification of only tyrosine residues to nitrotyrosine was evident from amino acid analysis of the acid hydrolysates of the modified proteins. The type B and E NTs could be completely detoxified without causing significant damage to their serological reactivities. Under similar modification reaction conditions, the type A NT was incompletely detoxified with some alteration in tis serological reactivity. Following relationship between molar excess of reagent over NT, number of nitrotyrosine residues formed and loss in toxicity emerged:

TAIAJ	Type A NT		Type B NT		Type E NT	
TNM molar excess	Nitro-Tyr.*	% loss toxicity	Nitro-Tyr.	% loss toxicity	Nitro-Tyr.	% loss toxicity
500	19.7	₹100	ND	100	24.5	100
125		99				-
100	ND	95	<1.0	>98	7.6	>99
80			1.2 (?)	91		
50	ND	85				>90
40			trace	70		
0	0	0	0	0	0	0

 ^{* -} number of nitro-tyrosine residues detected
 ND = is not detectable, Number of Tyr residues in types A, B, and E NTs are
 71, 81, 70, respectively.

4. <u>SECOND GENERATION TOXOID</u>:

The completely detoxified type B and E NTs, used as toxoid, elicited antibodies in rabbits. The antiserum precipitated and neutralized the homologous NT. Two separate batches of each of these toxoids were prepared for immunizing rabbits in separate groups. The two toxoids, type B and E, were prepared with >99% pure NTs as tested by SDS-PAGE whereas the traditional toxoids produced with formaldehyde are very crude preparations of the NT (~90% impure). Chemical modification induced by tetranitromethane is more specific than the products that form during ~7 days of reaction between a

protein and formaldehyde. The toxoids produced with tetranitromethane may be considered as a second-generation toxoid, compared with the first-generation toxoid (crude preparation of NT detoxified with formaldehyde).

5. TERTIARY STRUCTURE OF NT:

The conformations of dichain type A (nicked by endogenous protease), single chain type E, and dichain type E NT (nicked by trypsin) were compared at different pHs using circular dichroism (CD) and fluroescence spectroscopy. The high degree of ordered secondary structure (a helix 28%, B sheet 42%, total 70%) found in type A NT at pH 6.0 was similar to that found at pH 9.0 (α 22%, β 47%, total 69%). The secondary structure of the single chain type E NT at pH 6.0 (α 18%, β 37%, total 55%) differed somewhat from these values at pH 9.0 (α 22%, β 43%, total 65%). The dichain type E NT at pH 6.0 assumed a secondary structure (α 20%, β 47%, total 67%) that seemed more similar to that of dichain type A than the single chain type E NT. Examination with the fluorogenic probe toluidine napthalene sulfonate revealed that the hydrophobicity of the type A and E NTs were higher at pH 9.0 than at pH 6.0. Also, the hydrophobicity of the dichain type E NT was higher than its precursor the single chain protein and appeared similar to that of the dichain type A NT. The CD and fluorescence studies indicate that conversion of the single chain type E NT to the dichain form (i.e. nicking by trypsin) induced changes in conformation.

Literature Cited

- 1. Sakaguchi, G. <u>Clostridium botulinum toxins</u>. Pharmacol. Ther. <u>19</u>, 165 (1983)
- Cardella, M. A. Botulinum toxoids. In: Botulism, proceedings of a symposium (Lewis, K. H. and Cassel, K. Jr. eds). p. 113. U.S. Public Health Service Publication No., 999-FP-1. Public Health Service, Cincinnati, OH (1964)
- 3. Hatheway, C. L., McCroskey, L. M., Lombard, G. L. and Dowell, V. R. Atypical toxin variant of <u>Clostridium botulinum</u> type B associated with infant botulism. J. Clin. Microbiol. <u>14</u>, 607 (1981)

DISTRIBUTION LIST

5 copies Commander

US Army Medical Research Institute of Infectious Diseases

ATTN: SGRD-UIZ-M

Fort Detrick, Frederick, MD 21701-5011

1 copy Commander

US Army Medical Research and Development Command

ATTN: SGRD-RMI-S

Fort Detrick, Frederick, Maryland 21701-5012

2 copies Defense Technical Information Center (DTIC)

ATTN: DTIC-DDAC Cameron Station

Alexandria, VA 22304-6145

1 copy Dean

School of Medicine

Uniformed Services University of the Health Sciences

4301 Jones Bridge Road Bethesda, MD 20814-4799

1 copy Commandant

Academy of Health Sciences, US Army

ATTN: AHS-CDM

Fort Sam Houston, TX 78234-6100